Breaking News: Favipiravir clears coronavirus in 4 days

Breaking News On Favipiravir Clinical Trials

favipiravir chemical structure

Chemical Structure

Cas: 259793-96-9

MF: C5H4FN3O2

Molecular Mass: 157.1

Chemical Name: 5-fluoro-2-oxo-1H-pyrazine-3-carboxamide

What is Favipiravir?

Favipiravir, an RNA polymerase (RdRp) inhibitor, is a broad-spectrum anti-flu virus ingredient. It works by acting on viral genetic copying to prevent virus reproduction. It was developed by Fujifilm Holdings as the original manufacturer. On March 24, 2014, the Ministry of Health, Labour and Welfare approved Fujifilm Holdings’ Favipiravir tablets for the treatment of new and recurrent influenza under the trade name Avigan.

As the leading Favipiravir Manufacturer in China, we are very concerned about the clinical trials of favipiravir for coronavirus.

After the breaking-out of the coronavirus in 2019, researchers have explored many antiviral drugs for a possible cure, new or old, such as remdesivir, chloroquine phosphate, Favipiravir, lopinavir/ritonavir, and Chinese Traditional medicine, acupuncture, even Tai Chi, etc. Favipiravir, as the second most popular remedy against coronavirus after Remdisvir from Gilead, has attracted many research institutions to launch clinical trials for COVID-19 pneumonia.

Favipiravir Clinical Trial Results

On Feb 14th, 2020, Preliminary clinical results of Favipiravir in China came out for the treatment of coronavirus pneumonia. It eliminated viruses within 4 days with good safety and tolerance.

Viral clearance has been the gold standard for evaluating the clinical efficacy of antiviral drugs. The clinical study conducted in Shenzhen showed that favipiravir relieved the coronavirus progression by accelerating virus clearance.

In this clinical trial, researchers treated 35 patients of COVID-19 pneumonia with Favipiravir (3200 mg on the first day, 1200 mg/day on the 2nd to 14th day, 600mg by twice daily and the virus was eliminated within 14 days). There was another group of 45 patients with COVID-19 pneumonia treated by lopinavir/ritonavir tablets (400mg / 100mg, twice daily orally) with matching age, gender, and disease severity by contrast.

Researchers compared the median time in the two groups from drug administration to virus clearance, chest imaging improvement rate and safety.

The comparison showed positive results on the favipiravir group: the median time was shorter for virus clearance, with a median (interquartile range) of 4 days (2.5-9 days) and 11 days (8-13 days) in lopinavir/ritonavir group, with significant differences between these two groups ( P <0.001).

After controlling for potential confounding factors (age, time to onset, fever) and other potential factors, Favipiravir remains an independent influencing factor for improved chest imaging and early virus clearance. Compared with the lopinavir/ritonavir group, the favipiravir group had fewer adverse reactions and better toleration. The research results have been submitted to the journal of the Chinese Academy of Engineering.

Fastest Drug Approval From China FDA

In 2016 Hisun Pharma from China signed an exclusive patent authorization agreement with Fuji Chemical and has been doing research on Favipiravir ever since.

On February 15th, 2020, Hisun Pharma announced that their Favipiravir tablets were formally approved by the State Food and Drug Administration to be marketed for the treatment of new or recurrent influenza in adults (only when other antiviral drugs are ineffective).

Due to the breaking-out of coronavirus, Hisun pharma went for the urgent submission of a marketing application to the State Food and Drug Administration.

The entire approval process, including drug acceptance from CDE (China Drug Evaluation), the approval of production and marketing, only took 15 days and it should be the fastest in China Drug Approval History to complete the whole process, from drug application to marketing.   

One representative from Hisun said: ‘Once Favipiravir is approved for marketing, it can be used by clinical experts in small-scaleto treat coronavirus pneumonia. If more clinical evidences show that favipiravir is effective in the treatment of COVID19 pneumonia, it will serve as another option to help the patients.’

What is favipiravir cost

If you are looking for Favipiravir for research, please check our price ideas as below:

For 10 grams our price is about 150usd/g. 

For costs of other quantities, please contact us directly.

Other possible cures for coronavirus

  1. Remdesivir
  2. Ritonavir with lopinavir
  3. Ribavirin
  4. Galidesivir(BCX4430)
  5. Disulfiram
  6. Chloroquine Phosphate
  7. Hydroxychloroquine Sulfate
  8. Nitazoxanide
  9. Umifenovir
  10. Oseltamivir Phosphate
  11. Danoprevir
  12. Brilacidin
  13. Darunavir with cobicistat
  14. Arbidol Hydrochloride with Umifenovir

References

This Post Has 2 Comments

  1. Danielvox

    COVID-19 CORONAVIRUS has SWEPT the PLANET!
    Be safe, jerk off here

    1. admin

      We just listed the clinical trials in China, Favipiravir tablets are quickly approved for critical times, those are the facts. Don’t be a **** please.

Leave a Reply